Crossmark

Cost-effectiveness of trifluridine/tipiracil (TAS102) for heavily pretreated metastatic gastric cancer

Crossref DOI link: https://doi.org/10.1007/s12094-019-02127-6

Published Online: 2019-04-30

Published Print: 2020-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhou, K.

Zhou, J.

Zhang, M.

Liao, W.

Li, Q. https://orcid.org/0000-0002-5158-3838
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (No. 81572988)

Science & Technology Department of Sichuan Province Funding Project (No. 2016FZ0108, 2018SZ0117)
License Information

Text and Data Mining valid from 2019-04-30
More Information

Article History

Received: 24 March 2019

Accepted: 22 April 2019

First Online: 30 April 2019

Compliance with ethical standards

:

: The authors declare that they have no conflict of interest.

: The manuscript does not contain clinical studies or patient data.

: Informed consent was obtained from all individual participants included in the study.